New online melanoma risk calculators critical to saving lives

New online melanoma risk calculators critical to saving lives

28 August 2020

Clinicians and their patients now have access to a series of online calculators which will assist in prevention, early detection and optimum treatment of melanoma, ultimately saving lives.

Developed by researchers at Melanoma Institute Australia and based on published risk prediction models, the three web-based calculators are housed on a new Melanoma Risk website launched today.

They predict a person’s risk of developing their first melanoma; their risk of developing a second or subsequent primary melanoma; and their risk of a primary melanoma having spread to nearby lymph nodes.

MIA Co-Medical Directors, Professor Richard Scolyer and Professor Georgina Long AO, said the risk calculators were the latest in the growing arsenal of early detection tools and ground-breaking treatments which they believed would culminate in achieving zero deaths from melanoma this decade.

‘Awareness, prevention, early detection and optimum treatment are key when it comes to tackling melanoma and saving lives from this disease,’ said Professor Richard Scolyer.

‘The online risk calculators are designed to inform discussions between clinicians and patients; two promote prevention and tailored skin surveillance programs for early detection and the third facilitates specialised treatment plans according to the specific patient’s risk,’ he said.

‘The development of these wonderful online tools is testament to the great work of many of our researchers and clinicians at MIA and will move us closer to reaching zero deaths from melanoma,’ added Professor Georgina Long AO.

Currently, Australia has one of the highest melanoma rates in the world with one person diagnosed every 30 minutes and one person dying every five hours from the disease.

The launch of the calculators comes amidst concerns the COVID-19 pandemic may have caused Australians to delay seeking checkups for melanoma and other cancers where early detection is vital for optimum outcomes.

Two of the calculators use patient information such as age, skin type, family history and sun exposure history to calculate individual lifetime risk of a person developing either their initial primary melanoma or a subsequent one. This information then guides discussions between the patient and the clinician about appropriate sun protection behaviours as well as the optimum schedule of skin checks to ensure early detection.

The third calculator predicts risk of disease having spread from a primary melanoma to nearby lymph nodes, and potentially metastasising to other vital organs. It takes into account additional clinical information about the primary melanoma as well as a patient’s age.

This calculator enables those deemed to be at low risk of disease spread to safely forgo surgery for a sentinel node biopsy. Conversely, it also detects patients at higher risk of disease spread, increasing potential for earlier identification of lymph node spread and activation of optimum treatment.

‘This calculator predicting risk of disease spread is particularly of benefit to older patients who are less likely to have melanoma spread to their lymph nodes, but who are at increased risk of complications that can come from additional surgery and general anaesthesia,’ added Professor Long AO.

The three web-based calculators can be accessed at www.melanomarisk.org.au

Stop the Spread campaign shortlisted
22 Jun 2016

Stop the Spread campaign shortlisted

MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.

Merkel Cell Carcinoma: the hidden skin cancer
22 Jun 2016

Merkel Cell Carcinoma: the hidden skin cancer

Merkel cell carcinoma is a rare but aggressive skin cancer that is often hard to diagnose.

A meeting of the minds
02 Jun 2016

A meeting of the minds

MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.

MIA's Dermatology services expanded
27 May 2016

MIA's Dermatology services expanded

We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.

5 Minutes with Maria Gonzalez
20 May 2016

5 Minutes with Maria Gonzalez

This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.

Melanoma eBook to educate GPs
12 May 2016

Melanoma eBook to educate GPs

MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.

5 Minutes with Dr Scot Ebbinghaus
05 May 2016

5 Minutes with Dr Scot Ebbinghaus

Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.

Opdivo available on PBS for advanced melanoma patients
01 May 2016

Opdivo available on PBS for advanced melanoma patients

A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients. 

5 Minutes with Dr Louise Jackett
27 Apr 2016

5 Minutes with Dr Louise Jackett

MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.

MIA patient's plight highlighted in ABC series
27 Apr 2016

MIA patient's plight highlighted in ABC series

MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.

Recruiting: Pregnancy and moles study
26 Apr 2016

Recruiting: Pregnancy and moles study

Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.

The role of radiotherapy in melanoma
22 Apr 2016

The role of radiotherapy in melanoma

New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.

Australian melanoma rates take the silver – and that's good news
31 Mar 2016

Australian melanoma rates take the silver – and that's good news

However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.

Australia unites taking small steps to make a big difference for melanoma research
23 Mar 2016

Australia unites taking small steps to make a big difference for melanoma research

Thank you to everyone involved in making Melanoma March 2016 a huge success

And they're off... Melanoma March 2016 begins!
29 Feb 2016

And they're off... Melanoma March 2016 begins!

Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.

5 Minutes with Carole Renouf
29 Feb 2016

5 Minutes with Carole Renouf

MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.

Opinion: Outing Melanoma
24 Feb 2016

Opinion: Outing Melanoma

In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma. 

Congratulations Professor Georgina Long
22 Feb 2016

Congratulations Professor Georgina Long

MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.

Melanoma March 2016: Where your funds are going
19 Feb 2016

Melanoma March 2016: Where your funds are going

Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform. 

New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
05 Feb 2016

New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors

New MIA-led research has been published in the Journal of Clinical Oncology.